Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
mds
Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with MDS
By Dross at 2010-11-30 02:12
 

 In patients with low and intermediate risk myelodysplastic syndrome and deletion 5q (del(5q)) treated with lenalidomide, monitoring of cytogenetic response is mandatory, since patients without cytogenetic response have a significantly increased risk of progression. Therefore, we have reviewed cytogenetic data of 302 patients. Patients were analyzed by karyotyping and fluorescence in situ hybridization. In 85 patients, del(5q) was only detected by karyotyping.

read more | 2 comments | 1797 reads

Pancytopenia MDS may reflect stromal changes and longer time to engraftment post transplant
|
By Dross at 2008-01-17 04:06
 

It has recently been shown that patients with myelodysplastic syndrome (MDS) may find that their time to stem cell engraftment post transplant is delayed beyond that seen by Acute Myeloid Leukemiaterm transplant patients (a more serious disease.) The thought behind these results is that the bone marrow's stroma (matrix cells) was not providing sufficient signal to the blood progenitor cells before the transplant took place, whereas the AML patients may have had progenitor cells with more serious mutations in their dna which would not have responded properly even if the stroma's signals were being provided. Therefore in many AML patients, transplanted stem cells are able to engraft quickly because the matrix environment is healthy and able to support the division and growth of new progenitors.

read more | 2 comments | 2444 reads

Scoring system identifies MDS patients who have low-risk disease but a poor prognosis
By Dross at 2007-12-22 21:51
 

HOUSTON - A new scoring system for a form of leukemiaterm known as myelodysplastic syndrome (MDS) identifies patients who appear to have low-risk disease but actually have poor prospects of survival, researchers at The University of Texas M. D. Anderson Cancer Center report online at the journal Leukemia.

"We know an undefined group of MDS patients who are classified as low-risk by our present prognostic models will at some point have a sudden worsening of their disease. Right now, we don't know who these people are, but if we can identify them, we can start those with a poor prognosis on early treatment," says lead author Guillermo Garcia-Manero, M.D., associate professor in M. D. Anderson's Department of Leukemia.

read more | 1844 reads

MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
By Dross at 2007-12-12 10:01
 

Pharmion Corporation (NASDAQ:PHRM) today announced interim data from a Phase 2 clinical trial evaluating three alternative five-day dosing schedules for Vidaza(R) (azacitidine for injection) that demonstrated safety and response profiles which are consistent with those achieved with the FDA-approved seven-day regimen, as reflected in rates of hematologic improvement (HI) and red blood cell (RBC) transfusion independence. These responses were observed in a broad range of MDS patients, including FAB low-risk patients. These data were presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Atlanta.

"The data from this study suggest that a five-day schedule is as effective as the currently approved seven-day schedule at achieving RBC transfusion independence and hematologic improvement in MDS patients," said Dr. Andrew R. Allen, executive vice president and chief medical officer of Pharmion. "A dosing schedule that circumvents the need for weekend dosing would provide a meaningful benefit in terms of convenience to these patients and clinicians."

read more | 6333 reads

Exjade®, a breakthrough once-daily oral iron chelator, receives first approval worldwide in the US
By Dross at 2007-10-18 02:10
 
  • Exjade offers new alternative to burdensome standard therapy in children and adults who require blood transfusions for chronic anemias
  • Approval makes iron chelation more accessible to patients suffering from diseases such as thalassemia, sickle cell and myelodysplastic syndromes

Basel, November 2, 2005 – Novartis announced today the first approval worldwide for Exjade® (deferasirox) – the first and only once-daily oral iron chelator – by the US Food and Drug Administration. Exjade has been approved for the treatment of chronic iron overload due to blood transfusions in adults and children age two and older.

read more | 5004 reads

The European Myeloma Platform Reports New Survival data for REVLIMID Presented at the International Myeloma Workshop in Greece
By Dross at 2007-07-03 10:55
 

The European Myeloma Platform (EMP) says updated data for previously treated patients on REVLIMID (lenalidomide) plus the steroid dexamethasone shows median survival of 35 months, nearly three years. The data are pooled from two large randomized controlled Phase III trials that enrolled more than 700 patients from nearly 100 clinical sites worldwide. These updated results were presented at the 11th International Myeloma Workshop in Kos, Greece.

"Here in Kos we are seeing what is truly a paradigm shift in treatment for multiple myeloma patients," said Greetje Goossens, EMP member and leader of the Belgium myeloma support group. "The experts here are saying that nearly three years of median over all survival for REVLIMID patients is the longest they have seen in myeloma to-date from large clinical trials."

read more | 2169 reads

Bone marrow microenvironment can contribute to blood cell disorder
By Dross at 2007-06-15 00:02
 

Disorders of blood cells may begin in the biological environment where the cells develop, not just with the cells themselves, according to a study from researchers at the Massachusetts General Hospital (MGH) and the Peter MacCallum Cancer Center (Peter Mac) in Melbourne, Australia. In the June 15 issue of Cell, the investigators describe finding that genetic alterations in the bone marrow of mice can cause a type of myeloproliferative syndrome, an overproduction of certain blood cells that also occurs in human patients.

“Previously all myeloproliferative syndromes have been considered to be intrinsic to the blood cells themselves,” says Louise Purton, PhD, of the MGH Center for Regenerative Medicine, formerly of Peter Mac, who led the study. “This discovery may help us find better therapies for these disorders, which can be quite difficult to treat, and also for some leukemias.”

read more | 1 comment | 3784 reads

Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Tr
By Dross at 2007-05-17 22:28
 

New updated results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) were presented today by Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, at the 9th International Symposium on MDS currently taking place in Florence, Italy. Breakthrough data presented at the meeting showed that Revlimid, or lenalidomide, can provide long-term survival benefit and prevent disease progression in MDS patients with chromosome 5q deletion.

"These landmark data demonstrate that Revlimid, in many cases, can help patients with MDS live transfusion free for several years. More importantly, we found that Revlimid can provide a significant long-term survival advantage, with 87 percent of cytogenic responders having a ten-year survival estimate," said Dr. List, Professor of Oncology and Medicine and Chief, Division of Malignant Hematology at Moffitt, and lead investigator of the study. "It is very rewarding to see patients treated with Revlimid, living longer, living three or four years transfusion free and having a better quality of life overall."

read more | 1854 reads

Risk Based Management
By Dross at 2007-03-09 05:41
 

 

Vidaza, Revlimid, or straight to stem cell transplant? 

A good review of current techniques used for the treatement of myelodysplastic syndromes

 [via Expanded Academic ASAP Document]:

read more | 2075 reads

Myelodysplastic Syndrome Basics I
By Dross at 2007-03-09 03:41

Myelodysplastic syndromes are a group of diseases in which the bone marrow does not make enough healthy blood cells.

 

Myelodysplastic syndromes are diseases of the blood and bone marrow. Normally, the bone marrow produces stem cells (immature cells) that develop into mature blood cells. There are 3 types of mature blood cells:

read more | 4001 reads

Myelodysplastic Syndromes
By Dross at 2007-03-08 04:01

Myelodysplastic syndromes (MDS) are a major and very personal target of this website. Because of this, I have found that I have been delaying the creation of this page as I have so much information I would like to include, all of it specific to an individual's FISH (cytogenetic, chromosomal) picture.

 

It also occurs to me that many patients that may stop by this site are missing information that could save their lives. Therefore I would like to "cut to the chase" if you will and direct you to where you should go in the meantime.

MDS is characterized by an excess of blasts in the Bone Marrow 5-20%. While you may avoid the thought of leukemiaterm when reading information on the internet, the ONLY difference between MDS and leukemia is that the term "leukemia" is only used when the number of blasts reaches 20% or more.

read more | 6 comments | 8551 reads

Seattle Genetics Granted Orphan Drug Designation for AML and Hodgkin’s Disease Drugs
By HCat at 2007-02-16 06:15
 

    The FDA has approved orphan drug status for Seattle Genetic’s two drugs SGN-33 and SGN-35. Orphan drug status allows Seattle Genetics to obtain marketing exclusivity of the drug upon approval. More importantly, it also allows Seattle Genetics an opportunity to obtain grant funding from the U.S. government to support clinical trials and defray costs. The Orphan Drug Act encourages companies to develop treatment for diseases that affect fewer than 200,000 people a year.

    SGN-33 has shown anti-tumor effects in phase I studies. SGN-33 (lintuzumab) is a humanized monoclonal antibodyterm that targets the CD33 antigen. SGN-33 is expected to enter clinical phase II by the end of 2007 testing mainly older patients with AML and MDS.

read more | 4060 reads

Phase I Trial of Rigel' Aurora Kinase Inhibitor Begins
By HCat at 2007-02-15 02:04
 

    Announced February 13th on Rigel's site, the second of several phase I studies to evaluate the safety and initial efficacy of the candidate R763 in different types of cancers is starting. The trials will tests the inhibitor in solid tumors, hematological malignancies, and in combination with standard therapies.

    Merck Serono licensed development and commercialization rights to R763 and Rigel's Aurora kinase program in October 2005. Aurora kinases are a family of kinases (proteins that put phosphate groups on other proteins) that regulate mitosis (cellular division). It is thought that these kinases are deregulated in cancer, and culture cell studies have shown Aurora kinases have anti-tumor effects.

read more | 3382 reads

Cytokine treatment during chemotherapy (Adjuvant Chemotherapy) linked with Leukemia
By raja at 2007-02-08 01:02
 

When a patient undergoes chemotherapyterm, all dividing cell types are affected. Cancers are rapidly dividing cells and this is the property that chemotherapy looks to exploit. Unfortunately, since this is a non-targeted approach, several other dividing cells types in the body are also affected. White blood cells are one such affected group of cells along with Red blood cells and platelets (which are all derived from the Bone Marrow, which is a rapidly dividing cell type). This depression of WBC numbers is known as the Myelosuppressive effect. This usually ends up being the limiting factor on how much dosage a patient can withstand. If too many WBCs are destroyed, then it will lead to a weakened immune system and that will lead to secondary infections and sepsis. So to counter this, patients undergoing chemotherapy to treat breast cancer are given a supplement of a certain kind of growth factors called Cytokines that stimulate the growth of subtypes of white blood cells.

read more | 3820 reads

Increase in Breast Cancer treatment related MDS when GCSF given with Chemo
By Dross at 2007-02-07 05:00
 

Please read the About Us section if you have been diagnosed with Treatment related MDS. Leave your questions in the forums and I will be happy to help you with the latest research.

 

    Women with breast cancer who receive compounds that stimulate white blood cell production to help their bodies better tolerate chemotherapyterm are at an increased risk of developing a type of leukemiaterm or a condition called myelodysplastic syndrome, according to a new study in the February 7 Journal of the National Cancer Institute.

 

read more | 4 comments | 8241 reads

Syndicate content
 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 08:32 AM.